Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study☆☆☆
Background/Aims
Low protein concentration in ascitic fluid has been identified as a risk factor for spontaneous bacterial peritonitis (SBP). Until now, primary prophylaxis has not been recommended in these patients. The aim was to investigate the efficacy of long-term administration of ciprofloxacin to prevent SBP.
Methods
One hundred cirrhotic patients with <1.5
g/dl of total protein in ascitic fluid were randomized prospectively, in a double blind fashion to receive ciprofloxacin 500
mg/day (n
=
50) or placebo (n
=
50) for 12 months.
Results
Baseline data were similar in both groups. In the ciprofloxacin group, SBP occurred almost four times less frequently than in the placebo group but it was not statistically significant. The probability of survival at 12 months was significantly higher in patients receiving ciprofloxacin (86% versus 66%) (p
<
0.04). SBP and sepsis were the most frequent causes of death in the placebo group whereas gastrointestinal bleeding was responsible for the most deaths in the ciprofloxacin group. The probability of remaining free of bacterial infections was higher in patients receiving ciprofloxacin (80% versus 55%) (p
=
0.05).
Conclusions
Patients with cirrhosis and low protein concentration in ascitic fluid are candidates to receive long-term prophylaxis to reduce the risk of infections and improve survival.
Keywords: Spontaneous bacterial peritonitis, Primary prophylaxis, Ciprofloxacin
To access this article, please choose from the options below
☆ The authors who have taken part in the research of this paper declared that they do not have a relationship with the manufacturers of the drug involved either in the past or present and they did not receive funding from the manufacturers to carry out their research. Trial registration number is CCT-NAPN-16065.
☆☆ This study was supported by a grant from the Consejo de Investigación en Salud del Gobierno de la Ciudad de Buenos Aires.
PII: S0168-8278(08)00082-2
doi:10.1016/j.jhep.2008.01.024
© 2008 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.
